| scholarly article | Q13442814 |
| P2093 | author name string | Ahmad A Tarhini | |
| William E Gooding | |||
| John M Kirkwood | |||
| Lisa H Butterfield | |||
| Yongli Shuai | |||
| Pawel Kalinski | |||
| P2860 | cites work | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? | Q28253687 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression | Q29615344 | ||
| Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial | Q30434151 | ||
| Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting | Q30444875 | ||
| Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. | Q33705930 | ||
| Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells | Q33748026 | ||
| Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression | Q33903025 | ||
| Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. | Q34371245 | ||
| High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update | Q34507305 | ||
| Immunotherapy for melanoma | Q34573035 | ||
| Immune surveillance of tumors | Q34579196 | ||
| Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. | Q34621389 | ||
| Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. | Q34657638 | ||
| Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade | Q34657684 | ||
| Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. | Q35222367 | ||
| Derangement of immune responses by myeloid suppressor cells | Q35573513 | ||
| The biology of myeloid‐derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity | Q35750663 | ||
| Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy | Q36108095 | ||
| Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma | Q36174230 | ||
| Clinical and immunologic basis of interferon therapy in melanoma | Q36190624 | ||
| Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma | Q36353361 | ||
| Cutaneous melanoma: available therapy for metastatic disease | Q36365463 | ||
| Principles and use of anti-CTLA4 antibody in human cancer immunotherapy | Q36389992 | ||
| Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment | Q36445938 | ||
| Mechanisms of immune evasion by tumors | Q36490750 | ||
| Tumor-driven evolution of immunosuppressive networks during malignant progression | Q36494855 | ||
| Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients | Q36658673 | ||
| Indoleamine 2,3-dioxygenase in immune suppression and cancer. | Q36737697 | ||
| CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion | Q36835173 | ||
| Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis | Q37040516 | ||
| Next generation of immunotherapy for melanoma | Q37210833 | ||
| Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. | Q37382380 | ||
| Myeloid-derived suppressor cell heterogeneity and subset definition. | Q37695457 | ||
| Prognostic significance of autoimmunity during treatment of melanoma with interferon | Q37833559 | ||
| Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients | Q37961577 | ||
| Raising the bar: the curative potential of human cancer immunotherapy. | Q37998451 | ||
| Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells | Q43745656 | ||
| Prognostic significance of autoimmunity during treatment of melanoma with interferon. | Q44019499 | ||
| Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma | Q45287769 | ||
| Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. | Q46106546 | ||
| Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion | Q46440292 | ||
| IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. | Q47883923 | ||
| Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? | Q51962635 | ||
| Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine | Q60311223 | ||
| Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells | Q68094084 | ||
| Increased expression of human monocyte HLA-DR antigens and Fc gamma receptors in response to human interferon in vivo | Q70163400 | ||
| Vitiligo in patients with metastatic melanoma: a good prognostic sign | Q71105100 | ||
| Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer | Q71258120 | ||
| High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 | Q73825066 | ||
| A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment | Q80726091 | ||
| Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign | Q84256128 | ||
| P433 | issue | 9 | |
| P921 | main subject | antibody | Q79460 |
| toll-like receptor | Q408004 | ||
| metastatic melanoma | Q18975855 | ||
| P304 | page(s) | 702-710 | |
| P577 | publication date | 2012-11-01 | |
| P1433 | published in | Journal of Immunotherapy | Q15763946 |
| P1476 | title | Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination | |
| P478 | volume | 35 |
| Q39666412 | A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. |
| Q21245488 | A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma |
| Q26796316 | Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12 |
| Q36061606 | Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma |
| Q93047683 | Blimp-1 Contributes to the Development and Function of Regulatory B Cells |
| Q27024438 | Cancer vaccines |
| Q44017442 | Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab |
| Q38887297 | IFN-λ cancer immunotherapy: new kid on the block |
| Q53491955 | Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). |
| Q35598991 | Immune checkpoint blockade and interferon-α in melanoma |
| Q37548776 | Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab |
| Q93189340 | Immune regulation and anti-cancer activity by lipid inflammatory mediators |
| Q36711007 | Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study |
| Q37684031 | Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma |
| Q37626265 | Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy |
| Q35608653 | Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition |
| Q55619003 | Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. |
| Q64094685 | Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma |
| Q38223250 | Myeloid-derived suppressor cell heterogeneity in human cancers |
| Q34250873 | Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients |
| Q36275124 | Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator |
| Q36642804 | PD-1 Blockade Expands Intratumoral Memory T Cells |
| Q37024260 | Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. |
| Q26742012 | Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting |
| Q38148980 | Safety biomarkers in preclinical development: translational potential |
| Q36206582 | Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma |
| Q28067023 | Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma |
| Q50116255 | Talimogene Laherparepvec: First in Class Oncolytic Virotherapy |
| Q38534285 | Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma |
| Q36869880 | Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors |
| Q38271877 | Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy? |
| Q35831375 | The combined molecular adjuvant CASAC enhances the CD8+ T cell response to a tumor-associated self-antigen in aged, immunosenescent mice |
| Q36283876 | The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis |
| Q37222132 | Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. |
| Q24618653 | Trial Watch |
| Q34810257 | Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy |
Search more.